Opening Bell



May 27, 2021

Market Outlook

Indian markets are likely to see a flattish opening on the back of mixed global cues and continuous decline in Covid-19 cases in the country being negated by worries about increase in inflation. However, global news flows and sector specific developments will be key monitorables.

Markets Yesterday

- Domestic markets ended higher tracking gains mainly in IT, auto and BFSI stocks, which were partially offset by losses in metals
- US markets ended higher amid optimism over reopening of the economy


Key Developments

- Sun Pharma's Q4FY21 revenues are likely to grow 7% YoY to ₹ 8760 crore led by 10% growth in domestic and 12% growth in both RoW and Emerging Markets. The US is expected to grow ~2.2% YoY to ₹ 2773 crore amid continued traction in speciality portfolio and decline in Taro sales. EBITDA margins are expected to improve 635 bps YoY to 23% mainly due to marketing, travel expenses and a better product mix. Adjusted PAT is expected to grow 120.2% to ₹ 1455 crore
- Eicher Motors is expected to report a steady performance in Q4FY21 amid nearly flat Royal Enfield (RE) volumes QoQ at 2.05 lakh units (up 26% YoY, 2% QoQ). Total operating income for Q4FY21 is expected at ₹ 2,951 crore (up 34% YoY, 4% QoQ) amid 2.5% QoQ blended rise in ASPs at RE to ₹ 1.43 lakh/unit. EBITDA margins are seen at 22%, down 180 bps QoQ, driven by rise in key input costs. Ensuing PAT is expected at ₹ 525 crore (up 73% YoY, -1% QoQ). VECV's segment share of profit is expected at ₹ 52.8 crore vs. ₹ 31.4 crore in Q3FY21 (volumes up 42% QoQ)

Nifty He	at Map)							
Bajaj Finserv	11,906 4.7%	Bajaj Finance	5,771 2.7%	Infosys	1,397 2.6%	Grasim Ind	1,409 2.5%	UPL	813 2.0%
Wipro	527 1.9%	Maruti	7,034 1.8%	IOC	112 1.5%	TechM	1,008 1.5%	L&T	1,473 1.5%
HDFC Ltd	2,568 1.5%	TCS	3,159 1.4%	M&M	821 1.2%	Hero Moto	2,965 1.2%	Sun Pharma	704 1.1%
Cipla	945 1.0%	Asian Paints	2,942 0.9%	Titan	1,583 0.9%	SBI Life	972 0.7%	HCL Tech	946 0.6%
Axis Bank	735 0.5%	Indusind Bank	998 0.5%	HUL	2,354 0.4%	Bajaj Auto	4,166 0.4%	Ultratech	6,581 0.4%
Reliance Ind.	1,970 0.4%	ICICI Bank	653 0.3%	Eicher	2,634 0.3%	SBI	414 0.3%	Nestle	17,541 0.1%
Shree Cement	27,077 0.1%	Tata Motors	316 0.1%	Divis Lab	4,099 0.0%	Bharti Airtel	526 -0.1%	HDFC Life	659 -0.1%
HDFC Bank	1,477 -0.1%	ITC	211 -0.1%	BPCL	472 -0.5%	Dr Reddy	5,285 -0.5%	Kotak Bank	1,741 -0.6%
Britannia	3,416 -0.7%	Adani Ports	758 -0.7%	ONGC	113 -1.1%	Coal India	146 -1.2%	Tata Consum	642 -1.2%
NTPC	111 -1.9%	Tata Steel	1,082 -2.1%	Hindalco	381 -2.6%	JSW Steel	682 -2.6%	Power Grid	226 -3.1%

Today's Highlights

Results: Sun Pharma, Eicher Motors, Page Industries, Phoenix Mills, Cadila Healthcare, Goodyear India, Dixon Technologies, Solar Industries, HEG, Navneet, Hawkins, Siyaram, Nesco



	Close	Previous	Chg (%)	MTD(%)	YTD(%)
Sensex	51,018	50,638	0.8	4.6	6.8
Nifty	15,301	15,208	0.6	4.6	9.4

Institutional Activity					
	CY19	CY20	YTD CY21	Yesterday	Last 5 Days
Fll (₹ cr)	40,893	64,379	30,897	242	1,429
DII (₹ cr)	44,478	-28,544	-11,536	-439	-2,351

World Indices – Monthly performance

NSE	BSE	Shanghai	France	Germany
15,301	51,018	3,593	6,392	15,451
5.6%	5.4%	4.4%	1.9%	1.0%
Dow Jones	U.K.	Nikkei	Kospi	Nasdaq
34,323	7,027	28,642	3,168	13,738
1.0%	0.9%	-1.2%	-1.5%	-2.5%

Commodities	Close	Previous	Chng (%)	MTD(%)	YTD(%)
Gold (₹/10 gm)	48,520	48,553	-0.1	3.8	-3.3
Silver (₹/kg)	71,368	71,811	-0.6	5.7	4.8
Crude (\$/barrel)	68.0	68.7	-0.9	1.2	31.3
Copper (\$/tonne)	9,929	9,868	0.6	1.0	28.1
Currency					
USD/INR	72.8	72.6	0.3	1.8	0.4
EUR/USD	1.2	1.2	0.3	2.0	0.3
USD/YEN	108.9	109.1	-0.2	0.3	-5.2
ADRs					
HDFC Bank	73.0	75.5	-3.3	3.9	1.0
ICICI Bank	17.7	17.8	-0.6	8.4	18.9
Tata Motors	21.4	21.5	-0.7	10.4	69.6
Infosys	18.7	18.7	0.3	3.6	10.5
Dr ReddysLabs	72.8	72.6	0.2	5.4	2.0
Wipro	7.6	7.6	-0.4	6.3	34.7

Corporate Action Tracker

Security name

JM Financial

Jagran Prakashan

Tata Consultancy Services

Key Economic Indicator	Period	Latest	Prior Values
RBI Cash Reserve Ratio	N/A	3.50%	3.00%
RBI Repo Rate	N/A	4.00%	4.00%
RBI Reverse Repo Rate	N/A	3.35%	3.35%
CPIYY	Apr	4.29%	5.52%
Current Account Balance	Q3	-1.7bln \$	15.1bln \$
Exports - USD	Apr	30.6 bln\$	34.5 bln\$
FX Reserves, USD Final	Mar	577 bln\$	585 bln\$
GDP Quarterly yy	Q3	0.40%	-7.50%
GDP Annual	FY20	4.20%	6.10%
Imports - USD	Apr	45.7 bln \$	48.4 bln \$
Industrial Output yy	Mar	22.40%	-3.60%
Manufacturing Output	Mar	25.80%	-3.70%
Trade Deficit Govt - USD	Apr	-15.1bln \$	-13.9bln \$
WPI Food yy	Apr	7.58%	5.28%
WPI Fuel yy	Apr	20.94%	10.25%
WPI Inflation yy	Apr	10.49%	7.39%
WPI Manuf Inflation yy	Apr	9.01%	7.34%

Ex Date

28-May-21

Action

Dividend 25-May-21

Buyback

Dividend

Record Date

27-May-21


Status

Ongoing


Price (₹)

15.00


0.50



ICICI Direct Research



Sectoral Performance – Monthly Returns (%) (Not Updated)



Key News for	Today		
Company/I	News	View	Impact
ndustry			
Bharat	BPCL's revenues increased 14.1% QoQ to ₹		
Petroleum	98755.6 crore while marketing sales were at	,	
Corporatio	11.2 MMT, 4.1% QoQ. On the refining front,	account of inventory and exceptional	
n (BPCL)	crude throughput was up 15.9% QoQ to 8.4	gains. Fuel demand reached near normal	
	MMT while reported GRMs at US\$6.6/bbl	level in Q4FY21. However, the second	
	were lifted by inventory gain of US\$4.2/bbl.	wave of Covid-19 and subsequent	
	Subsequently, EBITDA was at ₹ 5057.9 crore,	restrictions have affected fuel demand in	
	17.5% QoQ (also supported by marketing	the current quarter (Q1FY22-TD).	\
	inventory gain of ₹ 1829 crore). The company	Improvement in GRMs and further	
	reported an exceptional gain of ₹ 6993 crore.	recovery in fuel demand will be important	
	Reported PAT was at ₹ 11940.1 crore, up	for BPCL's profitability in the near term.	
	329.9% QoQ. The company announced final	The progress on divestment and response	
	dividend of ₹ 58/share	by potential bidders will be the key	
		monitorable for the stock price	
		performance	

🌈 Opening I	Bell	ICICI Direct Research	
Pfizer Ltd	FY21 revenues grew 4.0% YoY to ₹ 2239 crore with hospital and vaccines business impacted amid the pandemic. EBITDA margins expanded 520 bps to 31.8% YoY due to a better overall operational performance. Decline in other expenses is likely on account of lower promotional and marketing activities related expenses. EBITDA grew 24.4% YoY to ₹ 712 crore. However, PAT de-grew 2.3% YoY to ₹ 498 crore. Delta vis-à-vis EBITDA was due to lower other income and tax reversals in the base year. Additionally, the company has proposed a ₹ 35 (special: ₹ 5 + final: ₹ 30) dividend for FY21	earlier quarters and Covid-19 related operational challenges, the company continues to deliver a decent set of numbers. Pfizer is following a measured approach with de-focusing and hiving off of tail brands and focusing on core strengths areas such as vaccines, pain management, vitamins, GI and CVS. The vaccines segment, led by Prevnar 13, especially, remains at the core of future growth and new launches. We continue to	
Gabriel India (GIL)	GIL posted strong Q4FY21 results. Net sales for the quarter were higher by 36.8% YoY, 8.2% QoQ to ₹ 581 crore. EBITDA margins rose 118 bps QoQ to 8.5% while PAT was at ₹ 27.7 crore, up 4.8% YoY, 18.2% QoQ. For FY21, net sales fell 9.1% YoY to ₹ 1,700 crore while margins slid 103 bps YoY to 6.3%. GIL declared final dividend and total dividend of ₹ 0.7/share and ₹ 0.9/share, respectively, for FY21	standout aspect of GIL's Q4FY21 performance and was in contrast to the rest of the automotive universe. The company continues to onboard new platforms in the PV space (has added Maruti Jimny, Tata Tiago & Tigor and the upcoming XUV700), and remains a prime	
Pricol Ltd	For Pricol, consolidated Q4FY21 sales were up 57.7% YoY, down 3.5% QoQ to ₹ 446 crore. Margins were lower by 264 bps QoQ to 12.4% while PAT fell 75.6% YoY, 93.3% QoQ to ₹ 1.4 crore. FY21 net sales rose 14% YoY to ₹ 1,413 crore with margins up strongly by 570 bps YoY to 12.6%	sequential basis was soft, with revenue dip being accompanied by higher costs under all heads on percentage of sales basis. PAT was impacted by exceptionally high	⇔
Sugar Industry	Indian sugar companies have started contracting sugar exports under OGL without any subsidy. According to Times of India, sugar mills have contracted for 1.5 lakh tonnes of exports without subsidy. It is important to note that global sugar prices have touched a high of 18.8 cents/lb in the last 15 days and are currently trading at 16.9 cents/lb	under OGL, which can result in total sugar export of 6.5-7.0 million tonnes in 2020-21 sugar season. We believe the government could either reduce or eliminate sugar export subsidy for 2021-22 sugar season.	


Key developments (Continued...)

- Cadila Healthcare's Q4FY21 revenues are expected to grow 4% YoY to ₹ 3904 crore with 20% YoY growth in domestic markets to ₹ 1071 crore supported by Covid related products being mostly offset by 9.4% YoY degrowth in US to ₹ 1595 crore amid weak flu season and competition in gLialda. EBITDA margins are likely to decline 59 bps YoY to 20.5% amid lower gross margins. However, net profit is expected to grow ~12% YoY to ₹ 486 crore on the back of lower finance cost
- We anticipate Page will report revenue growth of 46% YoY to ₹ 788 crore, driven by 36% growth in volumes and ~7% higher ASPs (owing to change in product mix). On account of positive operating leverage, we expect EBITDA margins to expand 540 bps YoY to 14.6%. We expect the company to report PAT of ₹ 54.5 crore (vs. ₹ 20.9 crore in Q4FY20 and ₹ 86.5 crore in Q3FY21)
- We expect Phoenix Mills' (Phoenix) Q4FY21 revenues to de-grow 1.5% YoY to ₹ 393.1 crore largely dragged by hospitality segment while retail is expected to show continued improvement (consumption likely to touch 100% of pre-Covid levels). Residential sales are likely to continue robust trajectory. At the PAT level, we expect ₹ 76.1 crore, up ~63% YoY, given the costs rationalisation and depressed base. Key monitorable will be outlook on business ahead amid second wave and lockdowns
- Manappuram Finance posted NII growth of 7.2% YoY to ₹ 1098 crore, in-line with its consolidated AUM growth of 7.9% YoY at ₹ 27200 crore. Opex was kept under control and was flattish on a yearly basis while provisions were up 33% sequentially to ₹ 107 crore. As a result, PAT came in at ₹ 468 crore, up 17.6% YoY. Gold AUM increased 12.4% YoY but was down 5.6% QoQ at ₹ 19077 crore. Gold tonnage during the quarter was down 9.7% YoY, 4.3% QoQ to 65.3 tonnes. The company conducted gold auctions worth ₹ 404 crore in March. GNPA for the company was at 1.9% vs. 1.3% QoQ
- Kewal Kiran Clothing reported a subdued set of results with revenues down 12.6% YoY to ₹ 110.7 crore (I-direct estimate: ₹ 125.2 crore). Change in channel mix (sales mainly through online and LFS) and higher discounting translated in gross margins contracting significantly by 713 bps YoY at 40.3%. Despite decline in selling (down 39% YoY) and employee expenses (down 8% YoY), EBITDA margins contracted 780 bps YoY to 9.2% (Q3FY21: 11.4%), with absolute EBITDA declining 53% YoY to ₹ 10.2 crore. Ensuing PAT declined 48% YoY to ₹ 8.2 crore (Q3FY21: ₹ 10.9 crore). The company continues to be net cash positive, with cash and investments worth ₹ 276 crore
- FDC's FY21 revenues remained flat, down 0.8% YoY at ₹ 1333 crore. EBITDA margins were up 529 bps to 25.1%, mainly due to lower other expenditure. Subsequently, EBITDA grew 25.7% YoY to ₹ 335 crore. Adjusted PAT grew 26.8% YoY to ₹ 304 crore
- According to Business line, banks have so far zeroed-in on 37 stressed assets, with exposure aggregating to about ₹ 92,000 crore, that can be transferred to the National Asset Reconstruction Company (NARCL)
- As per press release, Divi's Labs is MSD's authorised API manufacturer for Molnupiravir and is allowed to supply this API to MSD's voluntary license partners (such as Sun Pharma, Cipla, Dr Reddy's, Natco among others) in India that have been recently signed
- Cadila Healthcare has signed a license supply and commercialisation agreement with TLC, Taiwan for AmphoTLC (liposomal Amphotericin B) for injection used in the treatment of Mucormycosis or Black Fungus in India. Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Cadila, and Cadila will commercialise the drug in India
- As per Savilla's India report in The Economic Times, real estate demand for date centres in India is set to rise by 15-18mn sq ft in the next four to five years due to adoption of 5G, Internet Of Things (IoT), Artificial Intelligence, increasing use of cloud services and smart cities. Data centres in India currently occupy 7.5 mn sq ft while more than 8 mn sq ft are under construction
- As per exchange4media, Zee Entertainment (ZEEL) has restructured its ad sales team in order to extract more ad revenue from top clients and to widen the pool of advertiser base from regional clusters. The company has roped in former Star India SVP- Ad sales Omkar Kore as National Head - Key Accounts (TV + Digital). Kore has 21 years of experience across media, FMCG, and B2B sales and marketing
- Cadila Healthcare has sought DCGI approval to undertake clinical trials for ZRC-3308 (Covimabs), a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) to treat mild Covid-19
- Video streaming platform Eros Now has said that it had 39.9 million total paid subscribers and 224 million registered users worldwide, as of March 31, 2021. This represents 10.6 million net new paid subscriber additions since March 31, 2020, an annual growth rate of 36.2%
- Amazon and MGM have announced that they have entered into a definitive merger agreement under which Amazon will acquire MGM for a purchase price of \$8.45 billion (valued at ~37x CY21E EBITDA). MGM has a vast catalogue with more than 4,000 films as well as 17,000 TV shows
- The Walt Disney Company Chief Executive Officer Bob Chapek has said that the company will shut down 100 TV channels in 2021 as it pivots to a digital-first strategy with Disney+ at the centre of it. In 2020, the company had closed 30 channels



Pivot Points						
Index/Stocks	Trend	Close	S 1	S2	R1	R2
SENSEX	Positive	51017.5	50735	50452	51188	51356
Nifty 50	Positive	15301.5	15224	15147	15349	15397
ACC Ltd	Neutral	1664.3	1653	1642	1677	1690
Axis Bank Ltd	Positive	2941.6	2918	2896	2956	2971
GODREJ PROPERTIE	Negative	1348.6	1336	1323	1361	1373
SBI	Positive	413.6	409	406	417	422
GRANULES INDIA	Negative	318.9	317	315	322	325
CUMMINS INDIA	Negative	802.7	788	775	823	845
Tata Motors	Positive	315.5	314	312	319	322
JSW STEEL LTD	Negative	682.2	673	665	690	699
BHARAT HEAVY ELE	Neutral	72.5	71	70	74	76
TCS	Positive	3158.5	3119	3081	3180	3203
HERO MOTOCORP LT	Positive	2964.7	2927	2891	2994	3023
CONTAINER CORP	Positive	666.6	659	652	677	688
MAHINDRA & MAHIN	Neutral	821.2	814	807	827	833
Reliance Industries	Neutral	1970.1	1965	1958	1979	1986
AUROBINDO PHARMA	Positive	1023.4	1013	1002	1039	1054
COAL INDIA LTD	Negative	145.7	144	143	147	149

Nifty Call – Put Strike (Number of shares in lakh) – May, 2021



Technical Outlook

Equity benchmarks extended winning streak over fourth consecutive session and concluded Wednesday's session at 15301, up 93 points or 0.6%. In the expiry induced volatile session, we expect index to trade with a positive bias amid stock specific action. Hence, use intraday dip towards 15252-15278 to create long for target of 15365.

The formation of higher high-low supported by rotational sectoral leadership highlights broader participation that supports our stance of Nifty challenging lifetime high of 15400 in coming sessions and eventually head towards revised target of 15700 in the month of June, as it is 123.6% external retracement of Feb-April Correction (15432-14151). Hence, any temporary cool off from here on should be capitalised as incremental buying opportunity in guality large cap and midcaps. During current up move off May low (14416), the secondary corrections have been shallower in nature, highlighting elevated buying demand. In the process, market breadth has improved which augurs well for durability of ongoing up trend.

Nifty 50	Intraday	Short Term
Trend	Up	Up
Support	15260-15210	14600
Resistance	15370-15410	15700
20 day EMA	0	14648.0
200 day EMA	0	13437.0

Advances/Declines			
	Advances	Declines	Unchanged
BSE	1904	1231	146
NSE	1243	732	69

Daily Tec	hnical Calls
Daily Tec	hnical Calls
1. Buy Ba	jaj Finance in the range of 5780.00-5786.00
2. Buy Mir	ndtree in the range of 2207.00-2211.00
All recom	nendations of May Future
See Mome	ntum Pick for more details

Intraday Derivative S	trategy
i) TVS Motor	
Buy TVSMOT May	Fut at 652.00-654.00
CMP: 650.70	
Target 1: 659.4	Target 2: 669.1
Stop Loss: 646.6	
ii) Indus Towers	
Sell BHAINF May F	Fut at 240.50-241.00
CMP: 241.70	
Target 1: 238.5	Target 2: 233.7
Stop Loss: 245	

See Derivatives view for more details

Opening Bell

ICICI Direct Research

Results/	Events Calenda	ır									
10	May Monday	11	May Tuesday	12	May Wednesday	13	May Thursday	14	May Friday	15	May Saturday
Intellect Firstsource Zydess Wellness Matrimony, Siemens Ltd. CH CPI YoY Huhtamaki CH PPI YoY KEC International, Granules		Voltas,Pidilite,Asian Paints,JSPL Saregama India,Apollo Tyres Sagar Cement,Happiest Minds		Mphasis,IEX US PPI MoM Brigade Enterprise Vedanta,Polycab Vardhman Special Steel		Dr.Reddy's,SKF India Balkrishna Ind., Escorts Cipla,Gokaldas Exports Anup Eng.,Oberoi Realty L&T, Jindal Stainless		Geojit Financial			
17 GRSE,MR 3i Infotech Butterfyl G Wabco Inc Bharti Airte	,Federal Bank andhimati lia	PI Ind.,Bri Jyothy Lal Jindal Sta	os,Chalet Hotels inless Hisar,Aarti Ind	TCI Expre Endurance Ineos Styr	May Wednesday Corporation Ltd. ss,JK Tyre a Technologies olution oY, JP Imports	Relaxo Fo Music Bro Havells In	May Thursday dia,KNR Const. potwear,Zee Ent. padcast,Taro US dia,EPL mi cement	Birlasoft,H Elgi Equip South Ind	May Friday ments,SBI dindalco,JSW Steel oments,Shoppers Stop ian Bank Greaves Cons.	Rallis,MC	terprise
24 Dalmia Bh Mahanaga Taj GVK H Ramco Ce	lotels	Transport TTK Prest AIA Engin		Kewal Kira Gabriel Ind	ints, Pricol Limited	Page Indu Eicher Mo	.,Solar Ind.	TV Today Sudarsha Sumitomo	May Friday ion Const.,NCC ,Jagran Prakashan n Chemicals,ABFRL o Chemicals,Hawkins ding,IPCA Labs	Neogen C Divi's Labs	s aily Engineering
31 Narayana Aurobindo	May Monday Hrudayalaya	Gujarat Gas, Balrampur Chini NRB Bearings		03 June Thursday Nucleus EU Services PMI US Services PMI		04 June Friday Moil Ltd. EU Retail Sales		05 CH Export CH Import CH Trade	S		
07 CH FX Re US Consu JP GDP Q	mer Credit	08 EU GDP C US Trade CH PPI Yo CH CPI Yo	Balance oY	09 Teamleas JP PPI (Ye			June Thursday sit Facility Rate al Budget Balance oY		June Friday ial Production acturing Output(MoM)	12 JK Cemer	June Saturday tt

Desult Drevi

Major Economic Events this Week Date Event Country Period Actual Expected 25-May CB Consumer Confidence US 117.2 121.7 May 25-May New Home Sales 1021K US Apr 863K 26-May Crude Oil Inventories EU May -1.622M 1.321M Date Event Country Period Expected Previous 27-May GDP QoQ 6.5% 6.4% US May 27-May Initial Jobless Claims US Apr 425K 444K 27-May Unemployment Rate JP May 2.7% 2.6% 28-May Consumer Confidence EU May -6.0 5.1 28-May FX Reserves 590.03B IN May -28-May Personal Spending US Apr 0.5% 4.2% 28-May Goods Trade Balance US -90.60B May -29-May Manufacturing PMI JP 53.6 May 29-May Bank Loan Growth IN 5.7% May 29-May Deposit Growth IN May 10.3% 29-May FX, Reserves USD IN May 589.47B

Company	Revenue	Chg(%)		EBITDA	Chg(%)		PAT	Chg(%)	
Crore	Q4FY21E	YoY	QoQ	Q4FY21E	YoY	QoQ	Q4FY21E	YoY	QoQ
Sun Pharma	8,760.0	7.0	-0.9	2,014.8	47.8	-16.3	1,454.6	120.2	-21.5
Phoenix Mills	393.1	-23.2	16.4	215.1	5.3	35.5	76.1	63.1	16.4
Page Industries	787.6	45.5	-15.0	161.5	177.8	-28.6	106.4	243.1	-30.8
Eicher Motors	2,951.0	33.7	4.3	648.0	50.0	-3.6	525.0	72.7	-1.5
Cadila HC	3,903.6	4.0	2.8	800.2	1.1	-0.8	485.7	12.0	-7.9

Recent Releases	
Date	Report
May 27,2021	Result Update- Transport Corporation
May 27,2021	Result Update- Thermax Limited
May 26,2021	Result Update- Computer Age Management Service
May 26,2021	Company Update- VIP Industries.
May 26,2021	Result Update - Bajaj Electricals



Pankaj Pandey

Head – Research pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

I/We, Pankaj Pandey, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number - INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as a customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.